natgillin/translations-raw huggingface dataset:
Method according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added prior to, during or after, and preferably after, a step of grinding said calcium carbonate-comprising material in said suspension. 
15.Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni 2-((1- metilpropil)aminojetanol dodan prije, za vrijeme ili nakon, poželjno nakon koraka mrvljenja navedenog materijala koji sadrži kalcijev karbonat u navedenu suspenziju.
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2; or 
varijabilno područje lakog lanca CDR2 sadrži SEQ ID NO: 11; i varijabilno područje lakog lanca CDR3 sadrži SEQ ID NO: 12.
The detectable label comprises a label selected from the group consisting of a hapten, radioactive isotope, an enzyme, a fluorescent label, a chemiluminescent label, and electro-chemiluminescent label, a first member of a binding pair, and a substrate for an enzymatic detection reaction. In one embodiment, the detectable label comprises an electrohemiluminescent label comprising a sulfo-TAG® label. 
Postupak prema zahtjevu 2, naznačen time što oznaka koja se može detektirati sadrži oznaku odabranu iz skupine koju čine radioaktivni izotop, enzim, fluorescentna oznaka, kemiluminiscentna oznaka i elektrokemiluminiscentna oznaka i supstrat za enzimsku reakciju detekcije, ili oznaka koja se može detektirati je Sulfo- TAG oznaka.
The method of claim 25, wherein therapeutically effective amount of Crenolanib or a salt thereof is provided as a single agent or in combination with another pharmaceutical agent in a newly diagnosed proliferative disease pediatric patient, to maintain remission, or a relapsed/refractory proliferative disease pediatric patient. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove soli osigurana kao jedini agens ili u kombinaciji s drugim farmaceutskim agensom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije ili subjektu s relapsiranom ili refraktornom akutnom mijeloičnom leukemijom (AML).
The method of claim 12 or 13, wherein substantial gelation occurs within about 2 hours, and/or wherein substantial gelation occurs in the time period ranging from about five minutes to about two hours, and/or wherein the treatment further comprises a salt solution, and/or wherein the silk fibroin is in the form of an aqueous solution having a pH that is about pH 4 or lower or is about pH 7.5 or higher. 
Postupak prema zahtjevu 12 ili 13, gdje se u biti geliranje događa u roku od oko 2 sata, i/ili gdje se u biti geliranje događa u vremenu u rasponu od oko pet minuta do oko dva sata, i/ili gdje obrada dalje obuhvaća otopinu soli, i/ili gdje je fibroin svile u obliku vodene otopine čiji je pH oko pH 4 ili niže ili je oko pH 7,5 ili više.
Detailed description of the figures 
Detaljan opis slika
The antibody, the conjugate, or the pharmaceutical composition of claim 21 wherein the cancer is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. 
Antitijelo, konjugat ili farmaceutska kompozicija za uporabu prema patentnom zahtjevu 25 gdje, bolest ili poremećaj je bolest povezana sa tumorom, pri čemu je bolest povezana sa tumorom poželjno izabrana iz grupe koja se sastoji od kancera dojke, kancera želuca, kancera jednjaka, kancera pankreasa, kancera pluća, kancera jajnika, kancera debelog crijeva, kolorektalnog kancera, kancera jetre, kancera glave i vrata, kancera žučne vrečice i njihovih metastaza.
The polymorph of Claim 1, for use in controlling an invertebrate pest. 
Polimorf iz Zahtjeva 1, naznačen time, što se koristi za kontrolu invertebratskih štetočina.
When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. 
Kada je oblik jedinice doziranja kapsula, može, uz materijale gore navedenog tipa, sadržavati i tekuću podlogu, poput masnog ulja.
A compound of any of items 37-41 wherein L is a polyethylene glycol linker. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da L je polietilen glikol linker.
The method of claim 2, wherein the denaturing solution comprises a solution containing (i) a chaotropic substance, (ii) a chelator, (iii) a buffer, and (iv) a reducing agent. 
naznačen time da otopina za denaturaciju sadrži otopinu koja sadrži (i) kaotropnu tvar, (ii) kelator, (iii) pufer, te (iv) redukcijsko sredstvo, poželjno, pri čemu otopina za denaturaciju sadrži
More preferably, said molecule comprises a 2'-O methyl phosphorothioate ribose. 
Oligonukleotid u skladu s patentnim zahtjevom 1, pri čemu je navedeni oligonukleotid 2'-O metil fosforotioat oligoribonukleotid.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
A pharmaceutical comprising the 1-thio-D-glucitol compound, the pharmaceutically acceptable salt thereof, or the hydrate of the compound or the salt according to claim 1, in combination with at least one pharmaceutical selected from the group consisting of an insulin sensitizing agent, which is selected from the group consisting of a PPAR-Y agonist, a PPAR-a/Y agonist, a PPAR-δ agonist and a PPAR-a/Y/δ agonist; a glycosidase inhibitor; a biguanide; an insulin secretion accelerator; an insulin preparation; and a dipeptidyl peptidase IV inhibitor. 
Farmaceutski pripravak prema zahtjevu 22, naznačen time da je farmaceutski pripravak za profilaksu ili liječenje dijabetesa, bolesti povezanih sa dijabetesom, ili dijabetskih komplikacija. Farmaceutski pripravak prema zahtjevu 21, naznačen time da nadalje sadrži najmanje jedno sredstvo za senzibilizaciju inzulina, koje je odabrano iz skupine koja sadrži PPAR-y agonist, PPAR-a/y agonist, PPAR-8 agonist i PPAR-a/y/8 agonist; inhibitor glukozidaze; bigvanid; akcelerator sekrecije inzulina; pripravak inzulina; i inhibitor dipeptidil peptidaze TV.
This makes it possible to see information provided on the inside or outside surface of the first and second outer part. 
To omogućava da se vidi informacija koja je predviđena na unutarnjoj strani ili na vanjskoj strani površine prvog i drugog vanjskog dijela.
The transmitter of any one of claims 8 and 9, wherein the L1 block has L1 signaling information for the data slice. 
Uređaj prema zahtjevu 8 ili 9, naznačen time, što L1 blok ima LI signalizacijsku informaciju za signaliziranje podatkovnog odsječka.
Replaceable filter device according to any one of the preceding claims, characterized in that the filter housing (1) is rectangular-shaped and that the filter device comprises two filter elements (2,2') with flat filter bed in the longitudinal direction of the filter housing (1). 
Zamjenjivi uređaj za filtriranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je zamjenjivi filtarski uređaj konfiguriran da se može podignuti pri pretovaru sa kamiona na spojnu platformu pomoću sredstava za podizanje.
One of those improvements is to provide a continuous and efficient slow release of the active substance during at least a period covering the 6th month after injection of the composition. To this effect the invention concerns a pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows: 
Farmaceutski pripravak pripremljen od mikročestica za sporo oslobađanje LHRH agonista triptorelina, naznačeno time što taj pripravak sadrži smjesu prve skupine mikročestica i druge skupine mikročestica, gdje a) = mikročestice te prve skupine su napravljene od kopolimera PLGA tipa u kojem je inkorporiran triptorelin u obliku peptidne soli netopljive u vodi; taj kopolimer obuhvaća najmanje 85% (molarno) mliječne kiseline i ima inherentnu viskoznost između 0.5 i 0.9 dl/g, kako je mjereno u kloroformu na 25"C i pri koncentraciji polimera od 0.5 g/dL; b) - mikročestice te druge skupine su napravljene od kopolimera PLGA tipa u kojem je inkorporiran triptorelin u obliku peptidne soli netopljive u vodi i koji obuhvaća količinu mliječne kiseline između 70% i 80% (molarno); mikročestice te prve i druge skupine dalje imaju raspodjelu čestica definiranu kako slijedi:
A composition according to claim 6, wherein the composition is administered orally, as a sustained release capsule or an enteric-coated capsule. 
Pripravak sukladno zahtjevu 4, naznačen time, da se pripravak daje oralno, kao kapsula s produljenim oslobađanjem ili enterički obložena kapsula.
Use of a diaminophenothiazinium compound in the manufacture of a medicament for use in a method of treatment or prophylaxis of a tauopathy condition in a patient, wherein the compound is selected from: ethyl-thioninium chloride (ETC), 
Uporaba spoja diaminofenotiazinija, naznačena time, da je za proizvodnju lijeka koji se upotrebljava u postupku liječenja ili profilakse stanja taupatije kod pacijenta, pri čemu je taj spoj odabran od sljedećih:
Use of a pharmaceutical composition as specified in claims 25 for the manufacture of a medicament for the treatment of tumors, wherein the second agent is an anti-EGFR antibody, and said engineered antibody prevents or delays re-growth of tumor after stop administering the engineered antibody. 
Farmaceutski pripravak kako je navedeno u zahtjevu 16 naznačen time da je za uporabu kod liječenja tumora, pri čemu anti-tumorsko protutijelo je anti-EGFR protutijelo, a navedeno genetički izmijenjeno rekombinantno protutijelo sprečava ili odgađa ponovni rast tumora nakon dovršetka davanja genetički izmijenjenog protutijela.
The resulting solution was extracted with ethyl acetate. 
Rezultirajuća otopina je ekstrahirana sa etil acetatom.
The compound for use according to claim 35 wherein: said disease is osteoarthritis, restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, inflammation, angiogenesis, pancreatitis, kidney disease, inflammatory bowel disease, myasthenia gravis, multiple sclerosis, or Sjoegren's syndrome; 
Spoj za upotrebu prema zahtjevu 18 naznačen time da je bolest osteoartritis, restenozis, arteroskleroza, poremećaj kosti, dijabetski retinopatitis, psorijaza, benigno uvećanje prostate, angiogeneza, pankreatitis, bolest bubrega, upalna bolest crijeva, ili multipla-skleroza.
Thus, in a further embodiment 1 substituent selected from any one of R1-R9, which is different from hydrogen, is present in either of the two phenyl rings, such as 1 substituent selected from R1-R5, or the substituent is selected from R6-R9. 
Tako je, u daljnjoj verziji 1 supstituent odabran iz bilo kojeg od R-R*, koji je različit od vodika, prisutan u bilo kojem od dva prstena fenila, poput 1 supstituenta odabranog iz R-R', ili je supstituent odabran iz R"-R*.
The composition of claim 25 in which the pH range of the composition is from 7.0 to 8.0. The composition of claim 16 wherein the cyclodextrin is present at a concentration from 2.5% to 40% weight/volume. 
Sastav prema zahtjevu 11, naznačeno time da je ciklodekstrin prisutan u koncentraciji od 0,5% do 40% masa/volumen, poželjno u koncentraciji od 2,5% do 20% masa/volumen.
A compound for use according to claim 1 or claim 2, wherein said subject is an opioid experienced, non-dependent opioid user. 
Spoj za uporabu sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, pri čemu navedeni subjekt ima iskustvo s opioidom, a nije ovisnik o opoidima.
Purge gas was nitrogen (N2) with a controlled flow of 50 mL/min. 
Plin za pročišćavanje bio je dušik (N2) s kontroliranim protokom od 50 mL/min.
means for obtaining layer-2 information including network information table, NIT from the signal frame, wherein the NIT includes a descriptor having the PLP identifier, an identifier of a transmission system, information for a tuning frequency of the transmission system, an active OFDM symbol duration field and a guard interval field, and means for obtaining the PLP identified by the PLP identifier in the layer-1 information and the data slice identified by the data slice identifier in the layer-1 information, wherein the PLP is mapped to a transport stream using the PLP identifier, the identifier of the transmission system, the information for a tuning frequency of the transmission system, the active OFDM symbol duration field and the guard interval field in the descriptor in the NIT; 
sredstva (1803) za dobivanje NIT uključujući identifikator PLP-a (PLP_id) i identifikator C2 sustava (C2_system_id) iz sloj 2, L2 informacije okvira signala, i dobivanje PLP-a koji odgovara identifikatoru PLP-a i identifikatoru C2 sustava uključenog u NIT; i sredstva (1804) za dobivanje prijenosnog toka prema kojem je PLP mapiran, gdje deskriptor C2 dostavnog sustava, uključujući identifikator PLP-a i identifikator C2 sustava u TS petlji NIT mapa, prenosi tokove do PLP-ova u podatkovnim komadima C2 sustava.
The aqueous composition as claimed in claim 1, wherein the composition contains at least one surfactant protein. 
Vodena kompozicija za primjenu u postupku sukladno zahtjevu 1 ili 2, naznačena time, što kompozicija sadrži najmanje jedan surfaktant protein.
The method of claim 2, wherein Ibuprofen formulation is filled in Non Polyvinyl Chloride "NPVC", Polypropylene Single Function Connector "SFC"-Port, Single Function Connector "SFC"-Cap & Polyisoprene Single Function Connector "SFC" -Rubber-Disc. 
Single Function Connector) "SFC"-ulaz, konektorom pojedinačne funkcije "SFC"-zatvarač, i poliizoprenskim konektorom pojedinačne funkcije "SFC" - gumeni-disk.
Har is a pyridinyl radical bi-substituted by 1-4C-alkoxy, or a salt, a N-oxide or a salt of a N-oxide of this compound. 
je vodik, Har je 1-metil-1H-piridin-2-on-5-il, ili njegov enantiomer, njegova sol, njegov N-oksid ili sol od enantiomera ili N-oksid od toga spoja.
Dragee cores are provided with suitable coatings. 
Za dražejne jezgre osiguravaju se pogodne obloge.
PPARa is also involved with the activity of fibrates and fatty acids in rodents and humans. 
PPARa. je također uključen u aktivnost fibrata i masnih kiselina kod glodavaca i ljudi.
-C(=O)R4, -C(=O)-OR4, -C(=O)-NR4R5 groups, wherein R4 and R5 independently from each other represent hydrogen atom, C1-C6 straight or branched alkyl group, or C3-C7 cycloalkyl group optionally substituted with C1-C4 alkyl group, 
grupe -C(=O)R4, -C(=O)-OR4, -C(=O)-NR4R5, naznačeno time da R4 i R5 nezavisno jedan od drugog predstavljaju atom vodika, C1-C6 ravnu ili razgranatu alkil grupu, ili C3-C7 cikloalkilnu grupu opcionalno supstituiranu s C1-C4 alkil grupom. i/ili solima i/ili stereoizomerima i/ili diastereomerima i/ili hidratima i/ili otopinama i/ili polimorfnim modifikacijama istih.
A method for applying a relatively small volume of biologically active or chemical substance to a relatively large volume of an agricultural crop comprising: 
Postupak za nanošenje relativno male količine biološki aktivne ili kemijske supstance u relativno veliku količinu poljoprivrednog usjeva naznačen time što obuhvaća:
This was used in the subsequent reaction without further purification. 
Ono je uporabljeno u sljedećoj reakciji bez dodatnog pročišćavanja.
A structure according to any preceding Claim, wherein the location of each anchor point on the craft is vertically spaced from its associated draw mechanism. 
Plovilo sposobno za morsku plovidbu u skladu sa patentnim zahtjevom 4, gdje je lokacija svake točke za sidrenje (12) ispod mehanizma za vuču sa kojim je povezana (14).
wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) at least one compound selected from compounds known for their fungicidal activity; and a method of controlling diseases on useful plants, especially rust diseases on soybean plants. 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži (A) spoj formule (I) pri čemu je R1 difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; te (B) spoj fluopiram.
The multipurpose airway device as claimed in any one of the preceding claims, in which the chosen elastomeric material of the plate has a high elastic limit but does not display plasticity in its working range, so that the lips of the patient function as a purse string largely because of the bulk of the orbicularis oris muscle even when it is relaxed and not contracting, whereby the rim around the perimeter of the plate resists distortion and when in place in the vestibule of the mouth sits outside the orbicularis oris muscle and especially at the corners of the mouth and so retains the plate even during positive pressure breaths and the plate is further supported in position in the vestibule of the mouth between the lips and cheeks, gums and teeth of the patient by the airway device traversing and firmly gripped in the central aperture of the plate. 
Višenamjenski uređaj za disanje sukladno bilo kojem prethodnom zahtjevu, u kojem je izabrani elastomerski materijal vrlo elastičan, ali prilikom upotrebe ne iskazuje plastičnost, pa se usne pacijenta ponašaju kao kesa, i to većinom radi pritiska sljepoočnog mišića čak i kad je isti opušten, a ne stegnut, pri čemu se obrub pločice ne izobličava, a kad je na svom mjestu u usnoj šupljini, nalazi se u uglovima usta i izvan je dosega sljepoočnog mišića te tako drži pločicu na mjestu čak i tijekom disanja uz pozitivni tlak, pločica se nadalje drži na mjestu u usnoj šupljini između usana i obraza, desnih i zubi pacijenta pomoću uređaja za disanje, koji prolazi i čvrsto je stisnut u središnjem otvoru pločice.
one or more aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in an amount such that the total amount of aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in the aqueous preparation is from 250 ppm to 5000 ppm, calculated relative to the weight of water in the preparation, and at least one source of a water soluble lithium compound in an amount such that the total amount of solubilised lithium in the aqueous preparation is from 1000 to 3000 ppm, calculated relative to the weight of water in the preparation, wherein the water soluble lithium compound is a polymeric salt of lithium selected from Li2Na2polyphosphate or lithium-sodium hexametaphosphate; 
jedan ili više biocida koji otpušta aldehid i/ili biocida s jednom ili više aldehidnih skupina u tolikoj količini da je ukupna količina biocida koji otpuštaju aldehid i/ili biocida s jednom ili više aldehidnih skupina u vodenom pripravku od 250 ppm do 5000 ppm, izračunata u odnosu na težinu vode u pripravku, i barem jedan izvor u vodi topljivih litijevih spojeva u količini tolikoj da je ukupna količina otopljenog litija u vodenom pripravku od 1000 do 3000 ppm, izračunato u odnosu na težinu vode u pripravku, pri čemu je u vodi topljivi litijev spoj polimerna sol litija izabrana od Li2Na2polifosfata ili litij-natrij heksametafosfata;
In analogy to example 1, 3 1 of poly-ethylhydrosiloxane were used instead of hexamethyldisilazane. 
Analogno Primjeru 1 umjesto heksametildisilazana koristi se 3 1 polietilhidrosiloksana.
The method according to claim 4, wherein, when the wet adhesive composition is obtained from the composition of (a), the plasticizer is contained in amounts ranging from 30% to 40% by weight of the total weight of said wet adhesive composition. 
Uporaba u skladu s patentnim zahtjevom 2, pri čemu, kada su navedeni adhezivni sastavi dobiveni od mokrog sastava tipa (a), oni sadrže količine plastifikatora u rasponu od 30-40% prema težini u odnosu na ukupnu težinu mokrih sastava.
A compound of formula (X): wherein R' is hydrogen and R is selected from benzyl, acetyl, benzoyl, trifluoromethanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl and benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from halogen, cyano and trifluoromethyl; or R' is trimethylsilyl and R is tert-butoxycarbonyl; or R and R' taken together with the nitrogen atom they are linked to form a phthalimido group; and wherein the line means that the double bond of the beta-enaminoketone group can be in cis or trans configuration. 
u kojem su X, R i R’ definirani gore. Postupak iz patentnog zahtjeva 7, naznačen time da u spoju formule (VI) R’ jest vodik, a R je odabran iz sljedeće skupine: benzil koji na aromatskom prstenu može biti supstituiran s do tri supstituenta odbranih od sljedećih: halogen, cijano i trifluometilna skupina; C1-C3 acil, C7-C11 aroil, C1-C3 alkilsulfonil, C6-C10 arilsulfonil, C1-C4 alkoksikarbonil, benziloksikarbonil koji na aromatskom prstenu može biti supstituiran s do tri supstituenta odbranih od sljedećih: halogen, cijano i trifluometilna skupina.
The compound of claim 1, represented by the following formula or a pharmaceutically acceptable salt thereof: 
. Spoj u skladu s patentnim zahtjevom 1, naznačen time što spoj ima formulu:
The particle size distribution has been calculated using the Fraunhofer algorithm. 
Veličinska raspodjela čestica izračunana je uporabom Fraunhofer algoritma.
The method of claim 21 or claim 22, further comprising thereafter performing a diagnostic test that assesses a characteristic of a tumor cell on the at least one segregated circulating tumor cell that was present. The method as claimed in claim 23, wherein the diagnostic test is binding with a tissue-specific antibody; AND/OR, wherein the diagnostic test is binding with a tumor-specific antibody; AND/OR, wherein the diagnostic test comprises analyzing nucleic acids obtained from the at least one segregated circulating tumor cell that was present; AND/OR, wherein the diagnostic test is assessing the proliferative capacity of the segregated circulating tumor cell; AND/OR, wherein the diagnostic test is microscopic observation of the morphology of the segregated circulating tumor cell. 
Postupak prema patentnom zahtjevu 7 ili patentnom zahtjevu 8 dalje obuhvaća izvođenje dijagnostičkog ispitivanja kojim se procjenjuje karakteristika tumorske stanice na jednoj ili više odvojenih CTC stanica. Postupak prema patentnom zahtjevu 9, naznačen time što spomenuto dijagnostičko ispitivanje pretstavlja vezivanje s tkivno specifičnim i/ili tumorski specifičnim antitijelom ili obuhvaća ispitivanje nukleinskih kiselina dobivenih od najmanje jedne odvojene CTC stanice. Postupak procjene učinkovitosti liječenja tumora kod subjekta oboljelog od tumora, postupak obuhvaća odvajanje CTC stanica iz uzoraka krvi dobivenih od subjekta prije i poslije tretmana korištenjem postupka prema bilo kojem od patentnih zahtjeva 4 do 6 i na taj način usporedbom koncentracija CTC stanica u uzorcima.
Alkynyl (K) is converted to an alkynyl ester of Formula (L, wherein R15 is C1-8 alkyl) by treatment with a strong base followed by reacting with a C1-8 alkyl chloroformate. 
Alkinil (K) se prevodi u alkinil ester Formule (L, gdje je R15 C,.g alkil) tretiranjem s jakom bazom nakon čega slijedi reakcija sa C;.g alkil kloroformatom, Prikladna jaka baza je alkil litij, na primjer ali bez ograničavanja, n-butil litij, t-butil litij i slično.
wherein (n) is an integer from 2 to about 4000, and unreacted p-nitrophenyl chloroformate; 
HR P20150247 T1 pri čemu (n) je cijeli broj od 2 do 4000, i neizreagirani p-nitrofenil kloroformat;